Eric Bell's Location
Greater Boston, United States, United States
Eric Bell's Contact Details
Eric Bell work email
- Valid
- Valid
Eric Bell personal email
n/a
Eric Bell phone numbers
About Eric Bell
• Goal-oriented scientist with a track record of translating novel biology to generate IND-ready therapeutic candidates • Skilled in developing and delivering pre-clinical translational strategy, novel in vivo models, and scientific rationale for additional clinical opportunities• Supervised teams of multidisciplinary scientists, initiated and managed relationships with multiple CROs to deliver decision enabling data packages• Experienced in building a network of KOLs and advocacy groups to help guide pre-clinical plans• Passionate about discovering and delivering therapeutics with innovation, adaptability, accountability, and resilience
Eric Bell Work Experience Details
-
Director Translational ScienceRectify Pharma Apr 2023 - PresentCambridge, Ma, Us• Developed the tactical and operational plan for in vivo pharmacology and translational efforts of Rectify's hepatobiliary programs• Generated and characterized two mouse models of hepatobiliary disease and used them to deliver in vivo PoC for first-in-class ABCB11/B4 dual PFM • Developed translational plans for core pipeline programs and programs that are external opportunities • Identified and facilitated outreach to KOLs for scientific feedback and HCP perspective for hepatobiliary diseases, ectopic calcification disorders, rare ophthalmology diseases, and rare CNS/PNS diseases.• Collaborated with colleagues to develop the ABC transporter knowledgebase culminating in a Trends in Molecular Medicine publication -
Associate Director BiologyRectify Pharma Jan 2022 - Apr 2023Cambridge, Ma, Us
-
Associate Director, Translational ScienceForma Therapeutics, Inc. Sep 2020 - Jan 2022Watertown, Massachusetts, Us• Responsible for translational science efforts in rare benign hematology • Leading translational science for etavopivat clinical development team and contributing to the scientific strategy for life cycle management• Developed in vivo pharmacology and translational strategy for rare benign hematology discovery programs• Delivered data package for a no-go decision on a discovery program saving multi-million-dollar investment on an IDD contract • Influenced scientific objectives of clinical exploratory endpoints through development and execution of an advisory board meeting -
Program LeadAmathus Therapeutics, Inc. Jul 2019 - Sep 2020• Drove the execution of research strategy developed as a consultant utilizing one internal direct report and external resources to reach a GO decision in polycystic kidney disease• Identified in vivo PKD models, initiated a breeding program for a genetic model at a CRO, and nominated small molecules based on in vitro activity, ADME, safety, and PK properties for in vivo evaluation• Developed integrated timelines for in vitro and in vivo activities with overall company timelines and corporate goals, presented work to upper management and involved in presenting to investors• Demonstrated translatability from in vitro to in vivo models of target engagement markers/biomarkers -
ConsultantAmathus Therapeutics, Inc. Mar 2019 - Jun 2019• Identified and developed a research strategy in peripheral indications to evaluate and validate a novel protein chaperone target • Established and executed in vitro strategy to identify target engagement markers and suitable biomarkers for pre-clinical translational work
-
Translational Biology And Drug Discovery ConsultantSelf-Employed Jun 2018 - Sep 2020HotSpot Therapeutics: Advise on CRO selection and oversee work, review data and experimental designMitobridge: Preparation and writing of biomarker IND report Modulus: Due diligence and competitive intelligence of oncology target, with an emphasis on pharmacology, differentiation from related targets, and enabling assaysBantam Pharmaceutical: Interrogated MoA of small molecule oncology program
-
Principal ScientistMitobridge, Inc. May 2017 - Jun 2018• Program Co-Lead responsible for concept, target validation, assay development and in vivo proof of concept studies of a small molecule program targeting Bach1 in sickle cell disease • Completed several key pharmacology studies and IND reports (cellular pharmacology, in vivo pharmacology, and biomarker) for PPARδ program (MA-0211 for Duchenne Muscular Dystrophy and Mitochondrial Myopathy)• Engaged and recruited key opinion leaders in sickle cell disease, mitochondrial myopathy, and fatty acid oxidation for advisory board and preclinical strategy• Managed assay development, pharmacodynamic experiments, PK/PD correlation, and in vivo proof of concept experiments at CROs and with academic collaborators• Lead the design and execution of GO/NO GO study implicating mitochondrial function in Chronic Fatigue Syndrome• Identified an indication expansion opportunity for a lead compound by implicating mitochondria modulation from metabolomics data set on patient plasma samples• Supervised a small multidisciplinary team and was promoted 3 times• This work resulted so far in two peer-reviewed publications and two patent applications
-
Senior Scientist, Translational BiologyMitobridge, Inc. Jan 2016 - May 2017
-
Scientist, Translational BiologyMitobridge, Inc. Sep 2014 - Dec 2015
-
Postdoctoral Fellow/Research ScientistMassachusetts Institute Of Technology Aug 2007 - Aug 2014Cambridge, Ma, UsResearch Scientist (8/2013-8/2014)Postdoctoral Fellow (8/2007-7/2013)Investigated the molecular genetics of aging and diseases of aging, with a focus on Sirtuins. Utilized both tissue culture systems and genetically engineered mouse models. Gained significant experience in metabolism and proteomics.• Work resulted in fourteen peer-reviewed publications and one patent• Discovered SirT3 is a viable therapeutic strategy in cancer and diseases driven by hypoxia-inducible factor, and developed a mouse model to show feasibility.• Major collaboration resulted in the discovery of reductive glutamine metabolism and its therapeutic potential in oncology• Identified a major role for SirT1 in male germ cell differentiation, and as a therapeutic target for male contraception• Supervised, trained and mentored four students and a visiting professor• Managed animal protocols and served as lab representative for MIT Committee on Animal Care -
Graduate StudentNorthwestern University, Feinberg School Of Medicine 2002 - 2007Investigated cellular oxygen sensing and biological outcomes to hypoxia.• Acquired 2 fellowships and 1 travel award, published 11 manuscripts in peer-reviewed journals.• Successfully Identified mitochondria as the cellular oxygen sensor.• Identified that HIF is necessary for the hypoxic extension of replicative lifespan and sufficient for normoxic extension of replicative lifespan.
-
Research TechnicianUniversity Of Chicago Jul 2000 - Jul 2002Responsible for basic lab management.• Published 2 manuscripts.• Investigated the resident proteins of cardiac caveolae.
-
Research TechnicianQuest Pharmaceutical Services Apr 1997 - Jun 2000UsValidated and performed metabolite extraction from biological samples.Prepared standards and extracted metabolites for LC-MS/MS.
Eric Bell Skills
Molecular Biology
Cell Biology
Biochemistry
Tissue Culture
Western Blotting
Cell Culture
Molecular Cloning
Pcr
Genetics
Mitochondria
In Vivo
Protein Purification
Metabolism
Fluorescence Microscopy
Mouse Models
Proteomics
Assay Development
Cancer
Molecular Genetics
Qpcr
Flow Cytometry
Protein Expression
Experimental Design
Hypoxia
Immunohistochemistry
Immunofluorescence
Southern Blot
Immunoprecipitation
Cancer Biology
Aging
Confocal Microscopy
Rnai
Site Directed Mutagenesis
Mammalian Cell Culture
Fplc
Scientific Writing
Facs
Animal Models
Epigenetics
Drug Discovery
Pharmacology
Leadership
Eric Bell Education Details
-
Northwestern UniversityCancer Biology -
University Of DelawareBiotechnology
Frequently Asked Questions about Eric Bell
What company does Eric Bell work for?
Eric Bell works for Rectify Pharma
What is Eric Bell's role at the current company?
Eric Bell's current role is Director Translational Science.
What is Eric Bell's email address?
Eric Bell's email address is eb****@****ics.com
What is Eric Bell's direct phone number?
Eric Bell's direct phone number is +161740*****
What schools did Eric Bell attend?
Eric Bell attended Northwestern University, University Of Delaware.
What skills is Eric Bell known for?
Eric Bell has skills like Molecular Biology, Cell Biology, Biochemistry, Tissue Culture, Western Blotting, Cell Culture, Molecular Cloning, Pcr, Genetics, Mitochondria, In Vivo, Protein Purification.
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial